Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MRNA > SEC Filings for MRNA > Form 8-K on 30-Nov-2012All Recent SEC Filings

Show all filings for MARINA BIOTECH, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for MARINA BIOTECH, INC.


30-Nov-2012

Entry into a Material Definitive Agreement, Other Events, Financial Statemen


Item 1.01 Entry Into a Material Definitive Agreement.

On November 28, 2012, Marina Biotech, Inc. (the "Company") entered into a License Agreement (the "License Agreement") with Protiva Biotherapeutics Inc., a wholly-owned subsidiary of Tekmira Pharmaceuticals Corporation (collectively, "Tekmira"), whereby the Company will provide Tekmira a worldwide, non-exclusive license to the Company's unlocked nucleobase analog ("UNA") technology for the development of RNA interference therapeutics. Tekmira will have full responsibility for the development and commercialization of any products arising under the License Agreement. In consideration for entering into the License Agreement, the Company will receive an upfront payment in the amount of $300,000, plus milestone payments upon the satisfaction of certain clinical and regulatory milestone events and royalty payments in the low single digit percentages on products developed by Tekmira that use UNA technology.

Tekmira may terminate the License Agreement for convenience in its entirety, or in respect of any particular country or countries, by giving 90 days prior written notice to the Company, provided that no such termination shall be effective sooner than August 28, 2013. Either party may terminate the License Agreement immediately upon the occurrence of certain bankruptcy events involving the other party, or, following the expiration of a 120 day cure period (60 days in the event of a default of a payment obligation by Tekmira), upon the occurrence of a material breach of the License Agreement by the other party.

The Company intends to submit a FOIA Confidential Treatment Request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, requesting that it be permitted to redact certain portions of the License Agreement. The omitted material will be included in the request for confidential treatment.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the License Agreement, a redacted copy of which will be attached as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012.



Item 8.01 Other Events.

On November 29, 2012, the Company issued a press release announcing that it had entered into the License Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.



Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No. Description

99.1 Press release of Marina Biotech, Inc. dated November 29, 2012.


  Add MRNA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MRNA - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.